- Brodalumab is associated with similar efficacy in patients with moderate to severe psoriasis with BMI ≥30 vs 2.
Why this matters
- Obesity is often expected to negatively affect therapeutic response in this population.
- Brodalumab efficacy was similar between patients with BMI ≥30 vs 2.
- At 12 weeks: ≥75% improvement in Psoriasis Area and Severity Index (PASI-75), 97.8% vs 97.5%; PASI-100, 49.5% vs 54.1%.
- At 52 weeks: PASI-75, 93.4% vs 87.3%; PASI-100, 64.8% vs 72.6%.
- Brodalumab was associated with higher PASI-100 rates than ustekinumab at 12 weeks in patients with BMI ≥30 kg/m2 (P=.001) and patients with BMI 2 (P=.002), and at 52 weeks in patients with BMI 2 (P=.002).
- Serious adverse event rates were similar between patients treated with brodalumab with BMI ≥30 g/m2 vs those with BMI 2.
- 687 patients with moderate to severe psoriasis, 40.9% with BMI ≥30 g/m2, were included.
- 248 patients received continuous brodalumab, 316 received continuous ustekinumab, and 123 initially receiving ustekinumab received rescue therapy with brodalumab because of the lack of clinical response.
- Funding: Ortho Dermatologics; Amgen Inc.
- Post hoc analysis not powered to evaluate differences in efficacy or safety based on BMI category.